| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 61,364 | 138,933 | ||
| Available-for-sale securities | 174,778 | 129,177 | ||
| Prepaid expenses and other current assets | 8,710 | 10,530 | ||
| Total current assets | 244,852 | 278,640 | ||
| Operating lease, right-of-use assets | 22,535 | 23,133 | ||
| Property and equipment, net | 4,356 | 4,317 | ||
| Other non-current assets | 247 | 278 | ||
| Restricted cash | 1,924 | 1,924 | ||
| Total non-current assets | 29,062 | 29,652 | ||
| Total assets | 273,914 | 308,292 | ||
| Accounts payable | 8,429 | 4,704 | ||
| Accrued expenses and other current liabilities | 19,050 | 16,546 | ||
| Operating lease liabilities | 2,032 | 1,943 | ||
| Finance lease liabilities | 281 | 953 | ||
| Derivative liabilities | 6,550 | 5,700 | ||
| Total current liabilities | 36,342 | 29,846 | ||
| Operating lease liabilities, excluding current portion | 19,624 | 20,155 | ||
| Total non-current liabilities | 19,624 | 20,155 | ||
| Total liabilities | 55,966 | 50,001 | ||
| Common stock, 0.001 par value - 240,000,000 and 120,000,000 shares authorized at september 30, 2025 and december 31, 2024, respectively 77,882,685 and 40,468,141 shares issued and outstanding at september 30, 2025 and december 31, 2024, respectively | 78 | 78 | ||
| Additional paid-in capital | 1,125,810 | 1,120,463 | ||
| Accumulated other comprehensive income | 48 | -38 | ||
| Accumulated deficit | -907,988 | -862,212 | ||
| Total stockholders equity | 217,948 | 258,291 | ||
| Total liabilities and stockholders equity | 273,914 | 308,292 | ||
Solid Biosciences Inc. (SLDB)
Solid Biosciences Inc. (SLDB)